Navigation Links
EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
Date:10/25/2007

Results Consistent with MKC-1 Akt-mTOR Inhibitor Mechanism

ROCKVILLE, Md., Oct. 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of results for its cell cycle inhibitor, MKC-1, in preclinical renal cell carcinoma (RCC) models. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Activation of the oncogenic kinase Akt and the mTOR pathway are known to be adverse prognostic factors and contributors to the pathology of metastatic RCC, therefore inhibitors of these pathways are of significant interest for treatment of this disease. Human RCC cell lines in vitro were shown to have marked sensitivity to MKC-1. MKC-1 inhibited both Akt and mTOR pathway activation in vitro, and was further evaluated in a preclinical model consisting of a xenograft of the human RCC cell line, Caki-1. Orally- administered MKC-1, but not sunitinib malate (Sutent(R)), significantly increased survival of tumor-bearing animals in this model. Examination of tumors following five days of oral treatment with MKC-1 revealed inhibition of the Akt-mTOR pathway, as well as decreased angiogenesis and cell proliferation within the tumors. These preclinical results support further evaluation of MKC-1 for the treatment of renal cell carcinoma.

MKC-1 is a novel, orally-active cell cycle inhibitor with in vitro and in vivo efficacy aga
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
7. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
8. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... England , July 28, 2014 ... is investing £2.5 million to help it meet ... consumer goods, healthcare, pharmaceuticals and logistics. Albion joins ... ) Over the past 18 ... in its platform, its management team and its ...
(Date:7/25/2014)... July 25, 2014  In today,s marketplace, launching multiple ... challenging - as is managing a portfolio of products ... it possible - or even preferable - to pool ... can you combine resources and activities, and what marketing ... These are just a few of the dilemmas facing ...
(Date:7/25/2014)... -- Smile Train and its technology partner BioDigital have been ... among leading global health innovations in The Hive at ... Washington, D.C. at The John F. Kennedy ... Train is honored to be represented through our partnership ... health and medicine that TEDMED unites each year," said ...
Breaking Medicine Technology:OmPrompt Funded for Customer Automation Management Market Expansion 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3
... March 11 Bone Biologics, Inc. announced today ... of Allowance of patent claims which strongly protects the ... of the UCB-1 recombinant protein wherein the mammalian cell ... patent continues the creation of a patent portfolio for ...
... Feb. 25 Dr. Robert B. Arnot ... Silent Threat," the result of months of comprehensive research ... surfaces are emerging as a key source of bacterial and ... and Chief Medical Educator of www.touchsurfaces.org , also offers ...
Cached Medicine Technology:Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process 2Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process 3Dr. Robert B. Arnot Releases White Paper on the Silent Threat of H1N1 and Other Infectious Diseases 2Dr. Robert B. Arnot Releases White Paper on the Silent Threat of H1N1 and Other Infectious Diseases 3
(Date:7/28/2014)... The American Society of ... engaged in the field of organ transplantation, today ... Immunology Research Network (TIRN), a professional network ... modern organ transplantation continues to diversify, AST determined ... more opportunities for physicians, scientists and researchers to ...
(Date:7/28/2014)... one of the UK,s most common respiratory diseases has ... disease (COPD) is the name for a collection of ... to the lungs. Often linked to smoking, it ... admissions in the UK, with a high proportion of ... , A team of researchers, led by ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 With California ... it is welcome news that a fire blanket ... current protection is under development by SunSeeker Enterprises, Inc. ... to protect spacecraft from the extreme heat of re-entry ... both firefighters and homes. , “Our firefighters routinely lay ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Drorit Silverman, ... unveiled new plans to raise investment capital through her ... fitness concept in the United States. , According to ... of 24/7 fitness centers provide a great window of ... rapidly expanding space. In addition to this, Silverman looks ...
(Date:7/28/2014)... Medicine (BUSM) report variants in a new gene, PLXNA4, ... (AD). The discovery of this novel genetic association may ... specifically. These findings appear in the Annals of ... dementia affecting 5.4 million Americans including 13 percent of ... percent of people age 85 and older. Genetic factors ...
Breaking Medicine News(10 mins):Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:Researchers identify potential biomarker for AD 2
... Community,in partnership with the Forum, Unveil Disease "Hot Spots" ... (KCP) - an alliance of patient advocates, ... improve quality of care for individuals with kidney disease ... regarding the racial disparity among those suffering from Chronic ...
... Sysmex America, Inc., a leading medical diagnostic instrument ... availability of the Sysmex WAM eLearning program to ... across the U.S. Sysmex WAM eLearning gives customers ... Sysmex WAM users and as a tool to ...
... entitled Motorcycle Cancer? is sending a ... seat extremely low frequency electromagnetic field (ELF EMF) ... Randall Dale Chipkar. "Science proves electromagnetic danger and ... read up to 500 milliGauss of ELF EMF ...
... PLC Systems Inc. (OTC Bulletin Board: PLCSF) announced today ... financial results for the fourth quarter and year ended December ... 2009. The company plans to host a conference call to ... day. The call may be joined via telephone by dialing ...
... Highland Good Steward Management ("HGSM") today announced it ... investment adviser, as a sub adviser to Highland ... HGSM focuses on incorporating environmental, social ... William "Doug" Douglass III, co-founder of K2, said, ...
... Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce ... Administration (FDA) Level II Baseline Inspection and received a ... standard for the FDA to periodically perform unannounced inspections ... the FDA validates the Company,s quality system and its ...
Cached Medicine News:Health News:Kidney Care Partners Raises Alarm on Racial Disparities in Kidney Disease; Joins With National Minority Quality Forum to Educate Public, Congress During National Kidney Month 2Health News:Kidney Care Partners Raises Alarm on Racial Disparities in Kidney Disease; Joins With National Minority Quality Forum to Educate Public, Congress During National Kidney Month 3Health News:Sysmex America Introduces On Demand Middleware Training Tool 2Health News:Motorcycle Cancer Risk: Motorcycle Cop Cancer Concern from ELF EMFs Penetrating Motorcycle Seats 2Health News:K2 Advisors Named Investment Advisor by Highland Good Steward Management 2Health News:Solos Endoscopy, Inc. Successfully Completes FDA Inspection 2
... is for arthroscopic and open soft tissue repair ... procedural steps. It may be used with ... in conjunction with,anchors or screws (including suture pre-assembled ... tip permits the placement of a variety of ...
Knot pusher/suture retriever...
... The RC Retractor comes ... allow for superficial or deep ... Retractor permits retraction in three ... inferior. The fiber optic ...
Shoulder rasp...
Medicine Products: